Compare Bristol-Myers Squibb Co (BMY) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs NRG Energy Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.5 (market cap $116.30B), while NRG Energy Inc trades at $137.48 (market cap $29.19B). The key difference: Bristol-Myers Squibb Co is far larger — about 4× NRG Energy Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | NRG | |
|---|---|---|
Market Cap | $116.30B | $29.19B |
Sector | Health | Utilities |
52-Week High | $62.37 | $184.03 |
52-Week Low | $42.60 | $120.65 |
Enterprise Value | $152.24B | $53.02B |
Dividend Yield | 4.42% | 1.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
NRG Energy trades at $139.48, down 0.67% on the day, with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 153.27 but attractive P/S of 0.86, while revenue grew to $30.71B in 2025. Analyst sentiment remains positive with 64% buy ratings, though technical indicators suggest near-term pressure with support at $138.
Outlook is cautiously optimistic given strong analyst support and dividend payments, but risks include high debt levels and volatile cash flows. Investors should weigh solid revenue growth against margin compression and elevated valuation multiples before positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
